SELLAS Life Sciences Group (SLS) Faces Trial Delay Scrutiny, Is The Stock Too Expensive?

SELLAS Life Sciences Group (SLS) is under scrutiny after a law firm began investigating the company’s delay in releasing results from its Phase 3 Galinpepimut S trial, which were triggered at the 80th patient death.

The investigation lands after a sharp swing in momentum for SELLAS Life Sciences Group. The stock has a 1-day share price return of 3.3% after a 7-day share price decline of 16.4%. The 90-day share price return of 44.8% and year-to-date share price gain of 168% sit against a very large 1-year total shareholder return and a roughly 7x 3-year total shareholder return, which together point to strong longer term gains, even as recent moves suggest rising concern around trial and disclosure risk.

Capitalize on the volatility around SELLAS Life Sciences Group by scanning a curated set of 16 high quality undiscovered gems with strong fundamentals that are still flying under most investors' radar.

SELLAS Life Sciences Group has moved sharply on trial news, yet the share price still sits far below the analyst target range. Are investors correctly discounting trial and legal risk, or is fair value sitting much higher on the page?

Preferred Price-to-Book of 17.1x: Is it justified?

Valuation on SELLAS Life Sciences Group is being driven by a rich price-to-book ratio, with the stock trading at 17.1x book value compared with a 5x peer average. At a last close of $11.66 and no meaningful revenue yet, the question for investors is whether that premium truly reflects future potential or simply trial optimism priced into the shares.

The P/B ratio compares the market value of the equity to the net assets on the balance sheet. For a late stage biotech like SELLAS Life Sciences Group that is still loss making and effectively pre revenue, investors often lean on this metric as a shorthand for how highly the market values its pipeline and intellectual property relative to hard assets.

With SLS currently reporting $0 in revenue and a net loss of $32.461m, the 17.1x P/B suggests that buyers are paying a steep premium for expectations around future growth and for GPS and SLS009 progressing through the clinic. That premium can reflect confidence in forecast revenue growth of 69.5% per year and expectations that the business may move toward profitability in the next 3 years, but it also means any disappointment around trials, financing, or legal overhang can hit a valuation that is already stretched.

The comparison against the broader US Biotechs industry is even starker. The sector average P/B sits at 2.2x, which means SELLAS Life Sciences Group trades at a multiple that is several times higher than many peers. That kind of gap points to a stock that is expensive on this preferred multiple, with little room for error if the pipeline or funding picture does not evolve in line with high expectations.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 17.1x (OVERVALUED)

Still, the SELLAS Life Sciences Group story can break quickly if the Galinpepimut S data disappoints or if the legal review around disclosure escalates.

Find out about the key risks to this SELLAS Life Sciences Group narrative.

Next Steps

High expectations and rising concern can coexist for SELLAS Life Sciences Group, so move quickly, review the underlying data, and weigh the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond SELLAS Life Sciences Group?

Do not get stuck on a single story. Use the Simply Wall St screener to uncover fresh opportunities that fit your risk level and income goals.

• Zero in on potential turnaround candidates with stronger balance sheets than their share prices suggest by scanning the 11 elite penny stocks with strong financials.
• Hunt for quality businesses trading below their estimated worth by reviewing the 33 high quality undervalued stocks.
• Prioritise sleep-at-night holdings by focusing on companies flagged in the 11 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com